Company intelligence / Profile preview
Vasopharm
Würzburg, Bavaria, Germanyvasopharm.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Vasopharm’s lead candidate, ronopterin (VAS203), has shown promising results in both Phase II and ongoing pivotal Phase III trials for traumatic brain injury. The drug demonstrated significant improvement in neurological outcomes compared to standard care, with the potential to become the first effective therapy for TBI patients. Post hoc analyses from these studies have been positive. The mechanism involves selective inhibition of iNOS to reduce neuroinflammation after trauma without affecting normal nitric oxide function.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Vasopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vasopharm.